@article {Bruel2022.03.30.22273175, author = {Timoth{\'e}e Bruel and Laurie Pinaud and Laura Tondeur and Delphine Planas and Isabelle Staropoli and Fran{\c c}oise Porrot and Florence Guivel-Benhassine and Mika{\"e}l Attia and St{\'e}phane Pelleau and Tom Woudenberg and C{\'e}cile Duru and Aymar Davy Koffi and Sandrine Castelain and Sandrine Fernandes-Pellerin and Nathalie Jolly and Louise Perrin De Facci and Emmanuel Roux and Marie-No{\"e}lle Ungeheuer and Sylvie Van Der Werf and Michael White and Olivier Schwartz and Arnaud Fontanet}, title = {SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine}, elocation-id = {2022.03.30.22273175}, year = {2022}, doi = {10.1101/2022.03.30.22273175}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The protective immunity against Omicron following a BNT162b2 Pfizer booster dose among elderly is not well characterized.Methods Thirty-eight residents from three nursing homes were recruited for the study. Antibodies targeting the Spike protein of SARS-CoV-2 were measured with the S-Flow assay. Neutralizing activities in sera were measured as effective dilution 50\% (ED50) with the S-Fuse assay using authentic isolates of Delta and Omicron.Results Among the 38 elderly included in the study, with median (inter-quartile range, IQR) age of 88 (81-92) years, 30 (78.9\%) had been previously infected. The ED50 of neutralization were lower against Omicron than Delta, and higher among convalescent compared to naive residents. During an Omicron epidemic affecting two of the three nursing homes in December 2021-January 2022, 75\% (6/8) of naive residents got infected, compared to 25\% (6/24) of convalescents (P=0.03). Antibody levels to Spike and ED50 of neutralization against Omicron after the BNT162b2 booster dose were lower in those with breakthrough infection (n=12) compared to those without (n=20): median of 1256 vs 2523 BAU/mL (P=0.02) and median ED50 of 234 vs 1298 (P=0.0004), respectively.Conclusion This study confirmed the importance of receiving at least three antigenic exposures to the SARS-CoV-2 Spike protein for achieving satisfactory neutralizing antibody levels. In this population, protection against Omicron infection was increased in individuals who had been previously infected in addition to the three vaccine doses. Thus, a fourth antigenic exposure may be useful in the elderly population to prevent infection with Omicron, a variant known for its high escape immunity properties.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWork in OS lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale (FRM), the European Health Emergency Preparedness and Response Authority (HERA), ANRS-MIE, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito, and IDISCOVR, TIMTAMDEN ANR-14-CE14-0029, CHIKV-Viro- Immuno ANR-14-CE14-0015-01 and the Gilead HIV cure program. AF lab is funded by the INCEPTION project (PIA/ANR-16-CONV-0005) and the Labex IBEID (ANR-10-LABX-62-IBEID). The COVID-Oise cohort is funded by Alliance Tous Unis contre le virus Institut Pasteur, AP-HP and Fondation de France.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was registered with ClinicalTrials.gov (NCT04644159) and received ethical approval by the Comite de Protection des Personnes Nord Ouest IV. Informed consent was obtained from the residents, or their relatives when the residents did not have full capacity to sign legal documents.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2022/03/30/2022.03.30.22273175}, eprint = {https://www.medrxiv.org/content/early/2022/03/30/2022.03.30.22273175.full.pdf}, journal = {medRxiv} }